Posts

Zhongmou Therapeutics Reports First-in-Human Success of Optogenetic Gene Therapy ZM-02 for Retinitis Pigmentosa

on

Vera Therapeutics Appoints James R. Meyers to Its Board of Directors

on

Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management

on

Imfinzi Gains FDA Approval for Early Gastric and GEJ Cancers; BiomX Nebulizer Faces FDA Scrutiny

on

Otsuka's Anti-APRIL Antibody (Voyxact/Sibeprenlimab) Receives FDA Approval for IgA Nephropathy (IgAN)

on

FDA Delays Decision on Ascendis' Dwarfism Drug by Three Months

on

FDA OKs Sarepta Study of New Immune Suppression Approach with Elevidys; Gilead Acquires Preclinical TREX1 Program

on

CMS Unveils Negotiated Prices for Ozempic, Wegovy, and Other Drugs in Second Round of IRA Talks

on

Zentek Appoints Mohammed Jiwan as CEO

on

Curapath and Cristal Therapeutics Sign Co-Exclusive License of CliCr Bioconjugation Platform

on

Dupixent Gains EU Approval as First Targeted Therapy for Chronic Spontaneous Urticaria in Over a Decade

on

Novartis Announces Plans to Lay Off 550 Workers at Swiss Factory

on

Pharma Faces Supreme Court Deadline as IRA Price Negotiation Takes Effect

on

FDA's Pazdur Raises Concerns Over Legality of National Priority Voucher Program Amid Internal Disagreement

on

Accelerating Breast Cancer Treatment Planning with Agentic AI: Recent Advances and Implementations (2025)

on

ASH 2025: Breakthroughs in In Vivo CAR-T Data from Kelonia; Phase 3 Wins for Lilly, J&J, and Novartis

on

FDA Approves Novartis' Itvisma: Expanding Gene Therapy to Older Spinal Muscular Atrophy Patients

on

Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting

on

Johnson & Johnson Halts Phase 2 Alzheimer’s Trial After Tau Antibody Failure

on

Bayer Stock Rallies as Next-Gen Blood Thinner Achieves Phase 3 Success

on

Novo Nordisk's Semaglutide Misses Key Goals in Closely-Watched Alzheimer’s Disease Phase 3 Trials

on

White House Requests Resignation of Top FDA Aide, Prompting Tensions with Commissioner Makary

on

As Drug Resistance Rises, GramEye and GSK Advance New AI-Led Infectious Disease Research

on

AstraZeneca Onshores Rare Disease Portfolio as Part of $50B US Investment Pledge

on

GSK and AnaptysBio Enter Legal Dispute Over Jemperli License Amid Allegations of Contract Breaches

on

Eli Lilly Becomes First Drugmaker to Reach $1 Trillion Valuation

on

FDA Breakthrough Designations Lead to Priority Reviews, Report Finds

on

FDA Grants Regeneron Two Eylea HD Approvals in One Day

on

Edgewise Therapeutics Appoints Christopher Martin to its Board of Directors

on

ViVac Pharma Appoints Keren Leshem as CEO to Advance RNA-LNP Cancer Immunotherapy

on

Oncolytics Biotech Provides Update on Special Meeting of Shareholders

on

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

on

Researchers Advance Toward Matching Patients with the Most Effective GLP-1 Drug for Personalized Obesity Treatment

on

EDAP Receives FDA 510(k) Clearance for Advanced Focal One Robotic HIFU System Enhancements

on

AI Proteins Raises $41.5M Series A to Accelerate AI-Designed De Novo Miniprotein Therapeutics

on

GSK and LTZ Therapeutics Announce $50M Partnership to Develop First-in-Class Myeloid Cell Engagers for Cancer

on

Agios' Sickle Cell Trial Falls Short as Mitapivat Fails to Significantly Reduce Pain Crises

on

PBMs and FTC Battle in Court Over In-House Insulin Pricing Challenge Intensifies

on

Novartis Raises Sales Targets for Key Cancer Drugs, Tweaks Yearly Growth Guidance

on